Skin Lesions in a Daclizumab-Treated Patient with Multiple Sclerosis

In 2019, a case was presented of a middle-aged man with multiple sclerosis who was treated with Daclizumab, a humanized monoclonal antibody against the D-subunit (CD25) of the high-affinity interleukin (IL)–2 receptor. The patient developed skin reactions that were difficult to evaluate. A biopsy from the plantar area showed hyperkeratosis and acanthosis, but no parakeratosis, and a discrete inflammatory infiltrate was noticed around vessels in the dermis. Treatment with fluconazole 50 mg/day for 10 days, moisturizers, and grade I topical steroids led to slight improvement. The treatment with daclizumab was not discontinued. The study concluded that the clinical efficacy and side effects of daclizumab needed further reporting and confirmation in clinical practice in the following years.